U.S. markets closed

Biostage, Inc. (BSTG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.40000.0000 (0.00%)
At close: 9:58AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close1.4000
Open1.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4000 - 1.4000
52 Week Range0.8000 - 4.8800
Volume685
Avg. Volume3,192
Market Cap13.144M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-0.6490
Earnings DateNov 13, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Biostage Reports Third Quarter 2020 Financial Results
    PR Newswire

    Biostage Reports Third Quarter 2020 Financial Results

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspanâ„¢ technology for the treatment of esophageal atresia and esophageal disease, today announced its financial results for the three and nine months ended September 30, 2020.

  • Biostage Reports Second Quarter 2020 Financial Results
    PR Newswire

    Biostage Reports Second Quarter 2020 Financial Results

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspanâ„¢ technology for the treatment of esophageal atresia and esophageal disease, today announced its financial results for the three and six months ended June 30, 2020.

  • Biostage Reports First Quarter 2020 Financial Results
    PR Newswire

    Biostage Reports First Quarter 2020 Financial Results

    Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing bioengineered organ implants based on the Company's novel Cellspanâ„¢ technology, today announced its financial results for the three months ended March 31, 2020.